Skip to main content

Advertisement

SpringerLink
Log in

Antibody-guided radiation therapy of cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkin's lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, has refrained RIT from outgrowing the experimental stage in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, a historical overview of the application of RIT is given and various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed. Finally, the clinical results of RIT of NHL, colorectal cancer, ovarian cancer, breast cancer, and renal cell cancer are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hajdu SI: 2000 years of chemotherapy of tumors. Cancer 103: 1097–1102, 2005

    Article  PubMed  Google Scholar 

  2. De Vita VT, Jr: The influence of information on drug resistance on protocol design: the Harry Kaplan Memorial Lecture given at the Fourth International Conference on Malignant Lymphoma, June 6–9, 1990, Lugano, Switzerland. Ann Oncol 2: 93–106, 1991

    Google Scholar 

  3. Bremers AJ, Kuppen PJ, Parmiani G: Tumour immunotherapy: the adjuvant treatment of the21st century? Eur J Surg Oncol 26: 418–424, 2000

    Article  CAS  PubMed  Google Scholar 

  4. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G: Immunology and immunotherapy ofcolorectal cancer. Crit Rev Oncol Hematol 46: 33–57, 2003

    PubMed  Google Scholar 

  5. Pullyblank AM, Monson JR: Monoclonal antibody treatment of colorectal cancer. Br J Surg84: 1511–1517, 1997

    Article  CAS  PubMed  Google Scholar 

  6. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer1: 118–129, 2001

    Article  CAS  PubMed  Google Scholar 

  7. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M:Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther 3: 107–121, 2003

    Article  CAS  PubMed  Google Scholar 

  8. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun 24: 951–957, 2003

    CAS  PubMed  Google Scholar 

  9. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH: Radioimmunotherapy of B-cellnon-Hodgkin's lymphoma. Eur J Nucl Med 28: 1725–1735, 2001

    Article  CAS  PubMed  Google Scholar 

  10. Koppe MJ, Bleichrodt RP, Oyen WJG, Boerman OC: Radioimmunotherapy of colorectal cancer.Br J Surg 2005; in press.

  11. Ehrlich P. Collected Studies on Immunology John Wiley. New York: 1906.

    Google Scholar 

  12. Gorer PA. The role of antibodies in immunity to transplanted leukaemie in mice. J Pathol Bacteriol 54: 51, 1942.

    Article  Google Scholar 

  13. Eisen HN, Keston AS. The immunologic reactivity of bovine serum albumin labeled withtrace-amounts of radioactive iodine (I-131). J Immunol 63: 71–80, 1950

    Google Scholar 

  14. Pressman D, Korngold L. The in-vivo localisation of anti-Wagner-osteogenic-sarcomaantibodies. Cancer 6: 619–623, 1953

    CAS  PubMed  Google Scholar 

  15. Beierwaltes WH. Radioiodine-labelled compounds previously or currently used for tumourlocalization. In Agency IAE (ed). Proceedings of an Advisory Group Meeting on Tumour Localization with Radioactive Agents. Panel Proceedings Series. Vienna, Austria: International Atomic Energy Agency pp. 47–56, 1974

  16. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. JExp Med 122: 467–481, 1965

    Article  CAS  PubMed  Google Scholar 

  17. Mach JP, Carrel S, Merenda C, Sordat B, Cerottini JC. In vivo localisation ofradiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted intonude mice. Nature 248: 704–706, 1974

    Article  CAS  PubMed  Google Scholar 

  18. Goldenberg DM, De Land F, Kim E, Bennett S, Primus FJ, van NJ, Jr., Estes N, De Simone P, Rayburn P. Use of radiolabeled antibodies to carcinoembryonic antigen for the detectionand localization of diverse cancers by external photoscanning. N Engl J Med298: 1384–1386, 1978

    Article  CAS  PubMed  Google Scholar 

  19. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefinedspecificity. Nature 256: 495–497, 1975

    CAS  PubMed  Google Scholar 

  20. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fvand comparison with other immunoglobulin forms. Cancer Res 52: 3402–3408, 1992

    CAS  PubMed  Google Scholar 

  21. Kim JK, Tsen MF, Ghetie V, Ward ES: Catabolism of the murine Ig G1 molecule: evidence thatboth CH2-CH3 domain interfaces are required for persistence of Ig G1 in the circulation ofmice. Scand J Immunol 40: 457–465, 1994

    CAS  PubMed  Google Scholar 

  22. Rennen HJ, Makarewicz J, Oyen WJ, Laverman P, Corstens FH, Boerman OC: The effect ofmolecular weight on nonspecific accumulation of (99m)T-labeled proteins in inflammatoryfoci. Nucl Med Biol 28: 401–408, 2001

    Article  CAS  PubMed  Google Scholar 

  23. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med43: 693–713, 2002

    CAS  PubMed  Google Scholar 

  24. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J: Microautoradiographicanalysis of the normal organ distribution of radioiodinated single-chain Fv and otherimmunoglobulin forms. Cancer Res 53: 3776–3783, 1993

    CAS  PubMed  Google Scholar 

  25. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS: Human antibodies with sub-nanomolar affinities isolatedfrom a large non-immunized phage display library. Nat Biotechnol 14: 309–314, 1996

    Article  CAS  PubMed  Google Scholar 

  26. Stabin MG: MIRDOSE: personal computer software for internal dose assessment in nuclearmedicine. J Nucl Med 37: 538–546, 1996

    CAS  PubMed  Google Scholar 

  27. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC: Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or(177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with smallperitoneal metastases of colorectal origin. J Nucl Med 45: 1224–1232, 2004

    CAS  PubMed  Google Scholar 

  28. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM: Selection of radioimmunoconjugates for the therapy of well-established ormicrometastatic colon carcinoma. Int J Cancer 72: 477–485, 1997

    Article  CAS  PubMed  Google Scholar 

  29. Stein R, Juweid M, Mattes MJ, Goldenberg DM: Carcinoembryonic antigen as a target forradioimmunotherapy of human medullary thyroid carcinoma: Antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs. Cancer Biother Radiopharm14: 37–47, 1999

    CAS  PubMed  Google Scholar 

  30. Cardillo TM, Ying Z, Gold DV: Therapeutic advantage of (90)yttrium- versus(131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res7: 3186–3192, 2001

    CAS  PubMed  Google Scholar 

  31. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ: The processing and fate of antibodies and their radiolabels bound to the surface of tumorcells in vitro: a comparison of nine radiolabels. J Nucl Med 35: 899–908, 1994

    CAS  PubMed  Google Scholar 

  32. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID: Comparative metabolism and retention ofiodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res56: 2123–2129, 1996

    CAS  PubMed  Google Scholar 

  33. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA: Radiation dosimetry results from a Phase IItrial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin'slymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 18: 165–178, 2003

    CAS  PubMed  Google Scholar 

  34. Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W: Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimericmonoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm 19: 466–477, 2004

    CAS  PubMed  Google Scholar 

  35. Buchegger F, Pelegrin A, Delaloye B, Bischof-Delaloye A, Mach JP: Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies inradioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med31: 1035–1044, 1990

    CAS  PubMed  Google Scholar 

  36. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO: Localization of monoclonal antibody G250and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 48: 738–743, 1991

    PubMed  Google Scholar 

  37. de Bree R, Roos JC, Quak JJ, den Hollander W, Wilhelm AJ, van Lingen A, Snow GB, Dongen GA: Biodistribution of radiolabeled monoclonal antibody E48 Ig G and F(ab')2 in patientswith head and neck cancer. Clin Cancer Res 1: 277–286, 1995

    PubMed  Google Scholar 

  38. Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine GM, Izon D, Gascon P: Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9)against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer73: 864–877, 1994

    CAS  PubMed  Google Scholar 

  39. Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, Goldenberg DM: Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEAmonoclonal antibody NP-4 F(ab')2. J Nucl Med 37: 1504–1510, 1996

    CAS  PubMed  Google Scholar 

  40. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM: Molecular advances in pretargeting radioimunotherapy with bispecificantibodies. Mol Cancer Ther 1: 553–563, 2002

    CAS  PubMed  Google Scholar 

  41. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH: Pretargeted radioimmunotherapy ofcancer: progress step by step. J Nucl Med 44: 400–411, 2003

    PubMed  Google Scholar 

  42. Furmanova P, Shaller C, Simmons H, Adams GP: An evaluation of the damage to normal tissuesresulting from radioimmunotherapy with anti-Her2 diabodies (abstract). Cancer Biother Radiopharm 2004; 19: 517.

    Google Scholar 

  43. Goodwin D, Meares C, Diamanti C, McCall M, Lai C, Torti F, McTigue M, Martin B: Use ofspecific antibody for rapid clearance of circulating blood background from radiolabeledtumor imaging proteins. Eur J Nucl Med 9: 209–215, 1984

    Article  CAS  PubMed  Google Scholar 

  44. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M, Siccardi AG: In vivo labelling of biotinylated monoclonal antibodies by radioactiveavidin: A strategy to increase tumor radiolocalization. Int J Cancer Suppl 2: 121–125, 1988

    CAS  PubMed  Google Scholar 

  45. Pimm MV, Fells HF, Perkins AC, Baldwin RW: Iodine-131 and indium-111 labelled avidin andstreptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonalantibody. Nucl Med Commun 9: 931–941, 1988

    CAS  PubMed  Google Scholar 

  46. Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Scassellati GA, Epenetos AA: Intraperitoneal radio-localization of tumors pre-targeted bybiotinylated monoclonal antibodies. Int J Cancer 45: 1184–1189, 1990

    CAS  PubMed  Google Scholar 

  47. Yao Z, Zhang M, Kobayashi H, Sakahara H, Nakada H, Yamashina I, Konishi J: Improvedtargeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonalantibodies through an avidin chase. J Nucl Med 36: 837–841, 1995

    CAS  PubMed  Google Scholar 

  48. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN: Streptavidindistribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: Theoretical and experimental pharmacokinetics. Cancer Res 54: 2166–2175, 1994

    CAS  PubMed  Google Scholar 

  49. Sung C, van Osdol WW: Pharmacokinetic comparison of direct antibody targeting withpretargeting protocols based on streptavidin-biotin binding. J Nucl Med 36: 867–876, 1995

    CAS  PubMed  Google Scholar 

  50. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW: Follow-up of relapsed B-celllymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologousstem-cell rescue. J Clin Oncol 16: 3270–3278, 1998

    CAS  PubMed  Google Scholar 

  51. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, GButchko D Fisher, Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bonemarrow support. N Engl J Med 329: 1219–1224, 1993

    Article  CAS  PubMed  Google Scholar 

  52. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T. Phase II trial of 131I-B1 (anti-CD20) antibody therapy withautologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336–340, 1995

    Article  CAS  PubMed  Google Scholar 

  53. Juweid ME, Blumenthal RD, Lew W, Hajjar G, Rubin AD, Goldenberg DM: Importance of timingof radioimmunotherapy after granulocyte colony-stimulating factor administration forperipheral blood stem cell harvest. Clin Cancer Res 1999; 5: 3337s–3342s

    CAS  PubMed  Google Scholar 

  54. Richman CM, De Nardo SJ, O'Grady LF, De Nardo GL: Radioimmunotherapy for breast cancer usingescalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral bloodprogenitor cell transfusions. Cancer Res; 55: 5916s–5920s, 1995

    CAS  PubMed  Google Scholar 

  55. Richman CM, De Nardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, De Nardo GL: Dosimetry-based therapy in metastatic breast cancerpatients using 90Y monoclonal antibody 170H.82 with autologous stem cell support andcyclosporin A: Clin Cancer Res; 5: 3243s–3248s, 1999

    CAS  PubMed  Google Scholar 

  56. Ychou M, Pelegrin A, Faurous P, Robert B, Saccavini JC, Guerreau D, Rossi JF, Fabbro M, Buchegger F, Mach JP, Artus JC: Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectableliver metastases from colorectal cancer. Int J Cancer 75: 615–619, 1998

    Article  CAS  PubMed  Google Scholar 

  57. Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Borjesson PK, Huijgens PC, Snow GB, van Dongen GA: Reinfusion of unprocessed, granulocyte colony-stimulatingfactor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonalantibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res8: 3401–3406, 2002

    CAS  PubMed  Google Scholar 

  58. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF: Serotherapy of a patient with a monoclonal antibody directed against a humanlymphoma-associated antigen. Cancer Res 40: 3147–3154, 1980

    CAS  PubMed  Google Scholar 

  59. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W: Low-versus high-dose radioimmunotherapywith humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of Bcell-associated malignancies. Clin Cancer Res 5: 3304s–3314s, 1999

    CAS  PubMed  Google Scholar 

  60. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, Wormann B, Brittinger G, Becker W: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphomawith the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cellsupport. Results of a pilot study. Cancer 94: 1363–1372, 2002

    CAS  PubMed  Google Scholar 

  61. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA: Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11: 2021–2029, 1993

    CAS  PubMed  Google Scholar 

  62. Davis TA, Kaminski MS, Leonard JP, Gregory SA, Wahl RL, Hsu FJ, Wilkinson M, Frankel SR, Serafini A, Zelenetz AD, Kroll S, Coleman M, Levy R, Knox SJ: Results of a randomizedstudy of Bexxar® (tositumomab or iodine I-131tositumomab) versus unlabeled tositumomab in patients with relapsed or refractorylow-grade or transformed non-Hodgkin's lymphoma (NHL). Proc Am Soc Hematology 2001;3503.

  63. De Nardo GL, De Nardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL: Fractionatedradioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 50: 1014s–1016s 1990

    Google Scholar 

  64. De Nardo GL, De Nardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol16: 3246–3256, 1998

    Google Scholar 

  65. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomaswith iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548–564, 1991

    CAS  PubMed  Google Scholar 

  66. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, orhumanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55: 5899s–5907s, 1995

    CAS  PubMed  Google Scholar 

  67. Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM: Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and(111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients withrelapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5: 3292s–3303s, 1999

    CAS  PubMed  Google Scholar 

  68. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL: 131I-tositumomab therapy as initial treatment for follicular lymphoma. NEngl J Med 352: 441–449, 2005

    CAS  Google Scholar 

  69. Linden O, Tennvall J, Cavallin-Stahl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjogreen K, Wingardh K, Strand SE: Radioimmunotherapy using 131I-labeledanti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.Clin Cancer Res 5: 3287s–3291s, 1999

    CAS  PubMed  Google Scholar 

  70. O'Donnell RT, De Nardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, De Nardo SJ: 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 forradioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 5: 3330s–3336s, 1999

    PubMed  Google Scholar 

  71. Postema EJ, Raemaekers JM, Oyen WJ, Boerman OC, Mandigers CM, Goldenberg DM, van Dongen GA, Corstens FH: Final results of a phase I radioimmunotherapy trial using(186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 9: 3995S–4002S, 2003

    CAS  PubMed  Google Scholar 

  72. Scheidhauer K, Schwarz K, von Schilling C, Schmidt B, Wolf I, Peschel C, Schwaiger M: Pradiktion von Remission und ereignisfreiem Uberleben nach Radioimmunotherapie (RIT) von Non-Hodgkin-Lymphomen (abstract). 41 Jahrestagung DGN 2003; V152.

    Google Scholar 

  73. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF: 131I-Anti CD20radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinicaltrial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.Cancer Biother Radiopharm 18: 513–524, 2003

    Article  CAS  PubMed  Google Scholar 

  74. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS: Multicenter phase II study of iodine-131 tositumomab forchemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin'slymphomas. J Clin Oncol 18: 1316–1323, 2000

    CAS  PubMed  Google Scholar 

  75. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I: Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonalantibodies. Blood 87: 3640–3649, 1996

    CAS  PubMed  Google Scholar 

  76. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ: Phase I/II trialof IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cellnon-Hodgkin's lymphoma. J Clin Oncol 17: 3793–3803, 1999

    CAS  PubMed  Google Scholar 

  77. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomizedcontrolled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versusrituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, ortransformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453–2463, 2002

    CAS  PubMed  Google Scholar 

  78. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R: Yttrium-90-labeled anti-CD20monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2: 457–470, 1996

    CAS  PubMed  Google Scholar 

  79. Postema EJ: Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med45: 2126–2127, 2004

    PubMed  Google Scholar 

  80. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1(anti-CD20) antibody. N Engl J Med 329: 459–465, 1993

    CAS  PubMed  Google Scholar 

  81. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol 14: 1974–1981, 1996

    CAS  PubMed  Google Scholar 

  82. Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC: Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled h LL2 (Epratuzumab) in nude micewith CD22-positive lymphoma. Cancer Biother Radiopharm 18: 525–533, 2003

    Article  CAS  PubMed  Google Scholar 

  83. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM: Radioimmunotherapy of non-Hodgkin's lymphomawith 90Y-DOTA humanized anti-CD22 Ig G (90Y-Epratuzumab): do tumor targeting and dosimetrypredict therapeutic response? J Nucl Med 44: 2000–2018, 2003

    CAS  PubMed  Google Scholar 

  84. Linden O, Tennvall J, Cavallin-Stahl E, Lindner KJ, Darte L, Ohlsson T, Hindorf C, Wingard K, Strand SE: A phase I/II trial with 90Y h LL2 in recurrent B-cell lymphomas.Preliminary results (abstract). Cancer Biother Radiopharm 15: 413, 2000.

    Google Scholar 

  85. Press OW: Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 26: 58–65, 1999

    CAS  PubMed  Google Scholar 

  86. TA Johnson OW Press Therapy of B-cell lymphomas with monoclonal antibodies andradioimmunoconjugates: the Seattle experience. Ann Hematol 79: 175–182, 2000

    Article  CAS  PubMed  Google Scholar 

  87. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-celllymphomas. Blood 96: 2934–2942, 2000

    CAS  PubMed  Google Scholar 

  88. Nademanee A, Moline A, Forman SJ, et al. A phase I/II trial of high-doseradioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) andcyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients withpoor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL) (Abstract). Blood 100: 182a, 2002.

    Google Scholar 

  89. Connors JM: Radioimmunotherapy—hot new treatment for lymphoma. N Engl J Med 352: 496–498, 2005

    Article  CAS  PubMed  Google Scholar 

  90. Jain RK: Physiological barriers to delivery of monoclonal antibodies and othermacromolecules in tumors. Cancer Res 50: 814s–819s, 1990

    CAS  PubMed  Google Scholar 

  91. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM: Comparison ofequitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancerxenografts. Cancer Res 54: 142–151, 1994

    CAS  PubMed  Google Scholar 

  92. Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC: Radioimmunotherapy and colorectal cancer. Br J Surg 92: 264–276, 2005

    Article  CAS  PubMed  Google Scholar 

  93. Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, III, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW: Phase I/II trial of combined 131I anti-CEA monoclonal antibodyand hyperthermia in patients with advanced colorectal adenocarcinoma. Cancer78: 1861–1870, 1996

    Article  CAS  PubMed  Google Scholar 

  94. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM: Phase I/II clinical radioimmunotherapy with aniodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody Ig G. J Nucl Med 38: 858–870, 1997

    CAS  PubMed  Google Scholar 

  95. Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM: Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonalantibody, MN-14, in gastrointestinal cancer. J Nucl Med 39: 34–42, 1998

    CAS  PubMed  Google Scholar 

  96. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM: Characterization ofsecond-generation monoclonal antibodies against carcinoembryonic antigen. Cancer71: 3478–3485, 1993

    CAS  PubMed  Google Scholar 

  97. Behr TM, Salib AL, Liersch T, Behe M, Angerstein C, Blumenthal RD, Fayyazi A, Sharkey RM, Ringe B, Becker H, Wormann B, Hiddemann W, Goldenberg DM, Becker W: Radioimmunotherapy ofsmall volume disease of colorectal cancer metastatic to the liver: preclinical evaluationin comparison to standard chemotherapy and initial results of a phase I clinical study.Clin Cancer Res 5: 3232s–3242s, 1999

    CAS  PubMed  Google Scholar 

  98. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W: Radioimmunotherapy ofsmall-volume disease of metastatic colorectal cancer. Cancer 94: 1373–1381, 2002

    CAS  PubMed  Google Scholar 

  99. Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM: Phase I radioimmunotherapy trial with iodine-131–labeledhumanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients withmetastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2: 31–42, 2002

    Article  CAS  PubMed  Google Scholar 

  100. Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE: Initial experience evaluating 90yttrium-radiolabeledanti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.Cancer Res 55: 5929s–5934s, 1995

    CAS  PubMed  Google Scholar 

  101. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA: A Phase I trial of90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracilin patients with metastatic colorectal cancer. Clin Cancer Res 9: 5842–5852, 2003

    CAS  PubMed  Google Scholar 

  102. Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA: A phase I radioimmunotherapy trial evaluating90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients withmetastatic CEA-producing malignancies. Clin Cancer Res 6: 3855–3863, 2000

    CAS  PubMed  Google Scholar 

  103. Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wormann B, Hiddemann W, Ringe B, Becker W: Radioimmunotherapy of colorectal cancer insmall volume disease and in an adjuvant setting: preclinical evaluation in comparison toequitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.Anticancer Res 19: 2427–2432, 1999

    CAS  PubMed  Google Scholar 

  104. Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R, Bormer O, Buchegger F, Mach JP, Burtin P. Antigenic sites in carcinoembryonic antigen. Cancer Res49: 4852–4858, 1989

    CAS  PubMed  Google Scholar 

  105. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D: Analysis of a humantumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res46: 850–857, 1986

    CAS  PubMed  Google Scholar 

  106. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of oncofetal antigentumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res46: 3118–3124, 1986

    CAS  PubMed  Google Scholar 

  107. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L: Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic coloncarcinoma. J Nucl Med 36: 586–592, 1995

    CAS  PubMed  Google Scholar 

  108. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, Colcher D, Schlom J, Shochat D, Lo Buglio AF: Dose fractionation of radiolabeled antibodies in patients withmetastatic colon cancer. J Nucl Med 33: 1648–1653, 1992

    CAS  PubMed  Google Scholar 

  109. Meredith RF, Khazaeli MB, Plott WE, Grizzle WE, Liu T, Schlom J, Russell CD, Wheeler RH, Lo Buglio AF: Phase II study of dual 131I-labeled monoclonal antibody therapy withinterferon in patients with metastatic colorectal cancer. Clin Cancer Res 2: 1811–1818, 1996

    CAS  PubMed  Google Scholar 

  110. Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G. Phase I study of intravenous Lu-labeled CC49 murinemonoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res1: 1447–1454, 1995

    CAS  PubMed  Google Scholar 

  111. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA: Phase II radioimmunotherapy trial with 131I-CC49 in colorectalcancer. Cancer 73: 1057–1066, 1994

    CAS  PubMed  Google Scholar 

  112. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ: Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinalepithelium. Biochem Biophys Res Commun 236: 682–686, 1997

    Article  CAS  PubMed  Google Scholar 

  113. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW: Thehuman A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulinsuperfamily. Proc Natl Acad Sci USA 94: 469–474, 1997

    Article  CAS  PubMed  Google Scholar 

  114. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 inpatients with advanced colon cancer. J Clin Oncol 12: 1561–1571, 1994

    CAS  PubMed  Google Scholar 

  115. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ: Phase I/II study of iodine 125-labeled monoclonal antibody A33 inpatients with advanced colon cancer. J Clin Oncol 14: 1787–1797, 1996

    CAS  PubMed  Google Scholar 

  116. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N: Quantitative analysis of antibody localization in humanmetastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol8: 1894–1906, 1990

    CAS  PubMed  Google Scholar 

  117. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G: The epithelial cell surfaceantigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer38: 47–53, 1986

    CAS  PubMed  Google Scholar 

  118. Meredith RF, Khazaeli MB, Plott WE, Spencer SA, Wheeler RH, Brady LW, Woo DV, Lo Buglio AF: Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic coloncancer. J Nucl Med 36: 2229–2233, 1995

    CAS  PubMed  Google Scholar 

  119. Pant KD, Dahlman HL, Goldenberg DM: A putatively new antigen (CSAp) associated withgastrointestinal and ovarian neoplasia. Immunol Commun 6: 411–421, 1977

    CAS  PubMed  Google Scholar 

  120. E Bombardieri, Ferrari L, Spinelli A, Maffioli L, Seregni E, Buraggi G: Radioimmunotherapyof ovarian cancer with radiolabelled monoclonal antibodies: Biological basis, presentstatus and future perspectives. Anticancer Res 17: 1719–1729, 1997

    CAS  PubMed  Google Scholar 

  121. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J: Complementation of intracavitary and intravenous administration of a monoclonalantibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218–4224, 1987

    CAS  PubMed  Google Scholar 

  122. Koppe MJ, Soede AC, Pels W, Oyen WJ, Goldenberg DM, Bleichrodt RP, Boerman OC: Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int JCancer 106: 965–972, 2003

    CAS  Google Scholar 

  123. Wahl RL, Fisher S: Intraperitoneal delivery of monoclonal antibodies: enhanced regionaldelivery advantage using intravenous unlabeled anti-mouse antibody. Int J Rad Appl Instrum B 14: 611–615, 1987

    CAS  PubMed  Google Scholar 

  124. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG: Theintraperitoneal delivery of radiolabeled monoclonal antibodies: Studies on the regionaldelivery advantage. Cancer Immunol Immunother 26: 187–201, 1988

    Article  CAS  PubMed  Google Scholar 

  125. Buijs WC, Tibben JG, Boerman OC, Molthoff CF, Massuger LF, Koenders EB, Schijf CP, Siegel JA, Corstens FH: Dosimetric analysis of chimeric monoclonal antibody cMOv18 Ig G in ovariancarcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med25: 1552–1561, 1998

    Article  CAS  PubMed  Google Scholar 

  126. Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E, Canevari S, Gadina M, Presti M, Marini A, Seccamani E: Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonalantibody. Eur J Cancer 27: 724–729, 1991

    CAS  PubMed  Google Scholar 

  127. Zanten-Przybysz I, Molthoff CF, Roos JC, Verheijen RH, van Hof A, Buist MR, Prinssen HM, den Hollander W, Kenemans P: Influence of the route of administration on targeting ofovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer92: 106–114, 2001

    PubMed  Google Scholar 

  128. Ito T, Griffin TW, Collins JA, Brill AB: Intratumoral and whole-body distributions of C110anti-carcinoembryonic antigen radioimmunotoxin after intraperitoneal and intravenousinjection: A quantitative autoradiographic study. Cancer Res 52: 1961–1967, 1992

    CAS  PubMed  Google Scholar 

  129. Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB. Antibody-guided irradiation of advanced ovariancancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5: 1890–1899, 1987

    CAS  PubMed  Google Scholar 

  130. Nicholson S, Gooden CS, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF, Epenetos AA: Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment ofadvanced ovarian cancer: A matched analysis. Oncol Rep 5: 223–226, 1998

    CAS  PubMed  Google Scholar 

  131. Epenetos AA, Hird V, Lambert HE, et al. The long term survival of patients with ovariancancer treated with radioimmunotherapy (abstract). Cancer Biother Radiopharm 15: 111, 2000.

    Google Scholar 

  132. Oyen WJ, Massuger LF, Verheijen RH, Seiden M, Benigno B, Lopes A, Soper J, Markovska J, Vyzula R, Lambert H, Epenetos A: Consolidation therapy with intraperitoneal R1549(Yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer: aphase III trial (abstract). Cancer Biother Radiopharm 19: 528, 2004.

    Google Scholar 

  133. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J: A monoclonalantibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen inhuman mammary carcinoma cell populations. Int J Cancer 29: 539–545, 1982

    CAS  PubMed  Google Scholar 

  134. Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L: Clinical pharmacology, metabolism, and tissuedistribution of 90Y-labeled monoclonal antibody B72.3 after intraperitonealadministration. J Natl Cancer Inst 83: 1629–1636, 1991

    CAS  PubMed  Google Scholar 

  135. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ: Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovariancancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5: 953–961, 1999

    CAS  PubMed  Google Scholar 

  136. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, Lo Buglio AF, Meredith RF: Intraperitoneal radioimmunotherapy ofovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65: 94–101, 1997

    CAS  PubMed  Google Scholar 

  137. Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, Lo Buglio AF: A Phase I study of combinedmodality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8: 2806–2811, 2002

    CAS  PubMed  Google Scholar 

  138. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM, Jr., Kilgore LC, Grizzle WE, Schlom J, Lo Buglio AF: Intraperitoneal radioimmunochemotherapy ofovarian cancer: A phase I study. Cancer Biother Radiopharm 16: 305–315, 2001

    Article  CAS  PubMed  Google Scholar 

  139. Miotti S, Facheris P, Tomassetti A, Bottero F, Bottini C, Ottone F, Colnaghi MI, Bunni MA, Priest DG, Canevari S: Growth of ovarian-carcinoma cell lines at physiological folateconcentration: effect on folate-binding protein expression in vitro and in vivo. Int JCancer 63: 395–401, 1995

    CAS  Google Scholar 

  140. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL, Bombardieri E: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur JCancer 31A: 686–690, 1995

    CAS  PubMed  Google Scholar 

  141. Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH: Radioimmunotherapy with intravenously administered 131I-labeled chimericmonoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 41: 1168–1176, 2000

    PubMed  Google Scholar 

  142. De Nardo SJ: Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 35: 143–151, 2005

    Google Scholar 

  143. Eskelinen M, Lipponen P, Hippelainen M, Seveus L, Syrajanen K: Expression of tumourassociated antigens 12H12, 2E11, 7A9, CEA and DF3 in human breast cancer. Anticancer Res13: 2399–2406, 1993

    CAS  PubMed  Google Scholar 

  144. Wong JY, Somlo G, Odom-Maryon T, Williams LE, Liu A, Yamauchi D, Wu AM, Yazaki P, Wilczynski S, Shively JE, Forman S, Doroshow JH, Raubitschek AA: Initial clinicalexperience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody andautologous hematopoietic stem cell support in patients with carcinoembryonicantigen-producing metastatic breast cancer. Clin Cancer Res 5: 3224s–3231s, 1999

    CAS  PubMed  Google Scholar 

  145. Wong JYC, Somlo G, Odom-Maryon T, et al. Initial results of a phase I trial evaluating(90)Y-chimeric T84.66 anti-CEA antibody and autologous stem cell support in CEA-producingmetastatic breast cancer (abstract). Cancer Biother Radiopharm 13: 314, 1998.

    Google Scholar 

  146. Richman CM, De Nardo SJ: Systemic radiotherapy in metastatic breast cancer using 90Y-linkedmonoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 38: 25–35, 2001

    CAS  PubMed  Google Scholar 

  147. De Nardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, De Nardo GL: Radioimmunotherapy for breast cancer using indium-111/yttrium-90Br E-3: results of a phase I clinical trial. J Nucl Med 38: 1180–1185, 1997

    Google Scholar 

  148. Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn SD, Butchko G. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-Br E-3 andautologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breastcancer: a phase I trial. Cancer Res 55: 5921s–5924s, 1995

    CAS  PubMed  Google Scholar 

  149. Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE: Monoclonal mouseantibodies raised against human lung carcinoma. Cancer Res 46: 3917–3923, 1986

    CAS  PubMed  Google Scholar 

  150. De Nardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, Kroger LA, Lamborn KR, Hellstrom KE, Hellstrom I, De Nardo GL: Radioimmunotherapy for advanced breastcancer using I-131-Ch L6 antibody. Anticancer Res 17: 1745–1751, 1997

    Google Scholar 

  151. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4: 2729–2739, 1998

    CAS  PubMed  Google Scholar 

  152. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E: Targeting of renal cell carcinomawith iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15: 1529–1537, 1997

    CAS  PubMed  Google Scholar 

  153. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E: Phase I radioimmunotherapy ofmetastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5: 3268s– 3274s, 1999

    CAS  PubMed  Google Scholar 

  154. Brouwers AH, Mulders PF, de Mulder PH, Buijs WC, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen W.J. Radioimmunotherapy using 131I-cG250 in patients withmetastasized renal cell carcinoma with two consecutive treatments at the maximal tolerateddose. Clin Cancer Res 2005; in press.

  155. Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ: Phase I clinical trial with fractionated radioimmunotherapyusing 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45: 1412–1421, 2004

    CAS  PubMed  Google Scholar 

  156. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, de Mulder PH, Corstens FH, Mulders PF, Oyen WJ: Targeting of metastatic renal cell carcinoma with the chimericmonoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 9: 3953S–3960S, 2003

    CAS  PubMed  Google Scholar 

  157. Bardies M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard JY, Mahe M, Fiche M, Lisbona A, Giacalone F, Meyer P, Gautherot E, Rouvier E, Barbet J, Chatal JF: Bispecific antibodyand iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid orsmall-cell lung cancer. J Nucl Med 37: 1853–1859, 1996

    CAS  PubMed  Google Scholar 

  158. Kraeber-Bodere F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardies M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 5: 3190s–3198s, 1999

    CAS  PubMed  Google Scholar 

  159. Vuillez JP, Kraeber-Bodere F, Moro D, Bardies M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF: Radioimmunotherapy of small cell lung carcinomawith the two-step method using a bispecific anti-carcinoembryonicantigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPAhapten: results of a phase I/II trial. Clin Cancer Res 5: 3259s–3267s, 1999

    CAS  PubMed  Google Scholar 

  160. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardies M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J: Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonicantigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeledhapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9: 3973S–3981S, 2003

    CAS  PubMed  Google Scholar 

  161. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM: Phase II trial ofyttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients withmetastatic colon cancer. Clin Cancer Res 6: 406–414, 2000

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

    Manuel J. Koppe, Frits Aarts & Robert P. Bleichrodt

  2. Department of Nuclear Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada

    Ernst J. Postema

  3. Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

    Manuel J. Koppe, Wim J. G. Oyen & Otto C. Boerman

Authors
  1. Manuel J. Koppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernst J. Postema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frits Aarts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wim J. G. Oyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert P. Bleichrodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Otto C. Boerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel J. Koppe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koppe, M.J., Postema, E.J., Aarts, F. et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 24, 539–567 (2005). https://doi.org/10.1007/s10555-005-6195-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-005-6195-z

Keywords

Search

Navigation